Akshay S. Desai, MD, FACC
Senior Physician; Director Cardiomyopathy and Heart Failure
Brigham and Women's Hospital

Printed as of 11/13/2026

Disclosures

Personal Commercial (51)

Company Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
Abbott Laboratories	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Alnylam	Research/Research Grants	Significant (>= $5,000)	*Other*
Alnylam	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Amgen Inc.	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Analog Medical Devices	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Anthos Therapeutics	Consultant Fees/Honoraria	Significant (>= $5,000)	*Vascular Medicine*
Anumana/nFerence	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
AstraZeneca Pharmaceuticals	Research/Research Grants	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Avalyn Pharma	Research/Research Grants	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Avania Clinical Research	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Avidity Biopharma	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Axon Therapeutics	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Baim Clinical Research Institute	Other - *Adjudicator for CEC*	Significant (>= $5,000)	*General Cardiology*
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Bayer Healthcare Pharmaceuticals	Research/Research Grants	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Biofourmis	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Boston Scientific	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
ClinChoice	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Colorado Prevention Center	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Corsera Health	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
CVS Caremark	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Cytokinetics	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
DevPro Biopharma	Research/Research Grants	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Duke Clinical Research Institute	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Edwards Lifesciences	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Endotronix	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
FIRE1 Foundry	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
GlaxoSmithKline	Consultant Fees/Honoraria	Significant (>= $5,000)	*Other*
ICON Clinical Research	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
iRhythm Technologies	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Medpace	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology*
Medtronic	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Merck & Co., Inc.	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
New Amsterdam	Consultant Fees/Honoraria	Modest (< $5,000)	*General Cardiology*
Novartis Corporation	Research/Research Grants	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Novartis Corporation	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Parexel	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Pfizer Inc	Research/Research Grants ‡ *GARDEN TIMI-75*	None ($0)	*Heart Failure and Cardiomyopathies*
Pharmacosmos	Research/Research Grants	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Regeneron	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
River2Renal	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Roche	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology*
scPharma	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Stanford Clinical Research Institute	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Teva	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
TIMI Study Group	Other - *Adjudication for CEC*	Significant (>= $5,000)	*General Cardiology*
Vectorious Medical Technologies	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Verve Therapeutics	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Volta medical	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (1)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
DTX Plus, Inc	Ownership Interest/Partnership/Principal	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*

Clinical Trial Enroller (1)

Trial Name	Trial Sponsor	Trial Funding Source
ALLAY-HF	Alleviant Medical	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (3)

Year	Case Title	Represented	Description	Compensation
Self				
2026	Endocarditis	Plaintiff	Delay in care related to failure to diagnose endocarditis	Significant (>= $5,000)
2019	Cardiomyopathy	Defendant	Faliure to diagnose and treat hemochromatosis involving the heart	Modest (< $5,000)
2018	Out of Hospital Cardiac Arrest	Plaintiff	Failure to defibrillate patient with available AED during out of hospital arrest	Modest (< $5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 4/6/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 4/6/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 4/6/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.